Vault Pharma’s technology platform uses the human vault particle to deliver peptide payloads for unique immune signaling. We exploit the natural function of the human vault particle which is an immunological signal alert progenitor. Natural vault function is most notably characterized by vault particles being rapidly and robustly ingested by antigen presenting cells, APCs, specifically macrophages and dendritic cells. This favorable and natural property of vaults sets in motion an elegant and robust immune response that is non-inflammatory and results in many propitious effects including stimulation of antigen specific CD4 and CD8 T cells. Recombinant Vaults Allow for Novel Access To Immune Responses Recent data in multiple animal and cell models both published and unpublished demonstrate that vaults can and do produce an elegant, sophisticated and highly desired immune response characterized by unusually high and previous undescribed cellular immune responses (both CD4 and CD8) without inflammation, or cytokine storm. Evidence demonstrates that VPI-101 elicits an enhanced TIL response which recognize and kill cancer. Furthermore, animal studies demonstrate that VPI-101 vaults down regulate the tumor immune suppressive environment; reduced immune suppressive cells (reduce effective response) like T-regulatory cells (Tregs), myeloid derived suppressor cells (MDSC), IL-10 T cells, and induce systemic antitumor responses (stimulating splenic T-cell lytic activity against parental tumor cells). Recombinant vault particles are safe and non-immunogenic. Human vaults are identical in every person; therefore, they can be delivered as an off-the-shelf therapeutic. Vaults are highly stable, scalable, and homogenous in production
